![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/0/0d/Gliclazide_ball-and-stick.png/640px-Gliclazide_ball-and-stick.png&w=640&q=50)
格列齐特
化合物 / 維基百科,自由的 encyclopedia
格列齐特(英語:Gliclazide),商品名为达美康。是一种磺酰脲类口服抗糖尿病药。 [1][2]. 格列齐特可以防止因高血糖引起的细胞凋亡,保护人体的胰岛β细胞。[3] 格列齐特还可以防止因2型糖尿病导致的动脉粥样硬化(防止动脉脂肪堆积)。[4]格列齐特在中国作为一线药物使用,应用极为广泛,而在其他国家却并不常用。Diamicron ( Gliclazide)
药理
事实速览 臨床資料, 商品名(英语:Drug nomenclature) ...
![]() | |
![]() | |
臨床資料 | |
---|---|
商品名(英语:Drug nomenclature) | 达美康 |
AHFS/Drugs.com | Micromedex详细消费者药物信息 |
懷孕分級 |
|
给药途径 | 口服 |
ATC碼 | |
法律規範狀態 | |
法律規範 | |
藥物動力學數據 | |
生物半衰期 | 10.4小时 |
识别信息 | |
| |
CAS号 | 21187-98-4 ![]() |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard(英语:CompTox Chemicals Dashboard) (EPA) | |
ECHA InfoCard | 100.040.221 ![]() |
化学信息 | |
化学式 | C15H21N3O3S |
摩尔质量 | 323.412 g/mol |
3D模型(JSmol(英语:JSmol)) | |
| |
|
关闭
格列齐特为胰島素增泌剂,通过抑制胰岛β细胞的ATP-sensitive potassium channel(英语:ATP-sensitive potassium channel),从而促进胰岛素的释放。
引用
- Ballagi-Pordány, György; Köszeghy, Anna; Koltai, Mária-Zsófia; Aranyi, Zoltán; Pogátsa, Gábor. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Research and Clinical Practice. 1990, 8 (2): 109–14. PMID 2106423. doi:10.1016/0168-8227(90)90020-T.
- Shimoyama, Tatsuhiro; Yamaguchi, Shinya; Takahashi, Kazuto; Katsuta, Hidenori; Ito, Eisuke; Seki, Hiroyuki; Ushikawa, Kenji; Katahira, Hiroshi; et al. Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism. 2006, 55 (6): 722–30. PMID 16713429. doi:10.1016/j.metabol.2006.01.019.
- Del Guerra, S; Grupillo, M; Masini, M; Lupi, R; Bugliani, M; Torri, S; Boggi, U; Del Chiaro, M; et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes/Metabolism Research and Reviews. 2007, 23 (3): 234–8. PMID 16952202. doi:10.1002/dmrr.680.
- Katakami, N.; Yamasaki, Y.; Hayaishi-Okano, R.; Ohtoshi, K.; Kaneto, H.; Matsuhisa, M.; Kosugi, K.; Hori, M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004, 47 (11): 1906–13. PMID 15565373. doi:10.1007/s00125-004-1547-8.